InfuSystem Holdings, Inc. ( (INFU) ) has shared an announcement.
InfuSystem Holdings, Inc. and its joint venture partner Sanara MedTech Inc. have secured an exclusive distribution agreement in the United States with ChemoMouthpiece, LLC for a novel oral cryotherapy device aimed at alleviating oral mucositis, a common side effect of chemotherapy. This partnership leverages InfuSystem’s extensive oncology network and Sanara’s strategic expertise, indicating a promising advancement for cancer patient care. The Chemo Mouthpiece® has received FDA clearance and comes with the backing of clinical validation, offering a new reimbursable treatment option for the estimated 500,000 to 1,000,000 U.S. patients affected annually by this painful condition.
See more data about INFU stock on TipRanks’ Stock Analysis page.
